Comparison of multiple vaccine vectors in a single heterologous prime-boost trial by Barefoot, Brice et al.
Comparison of multiple vaccine vectors in a single heterologous
prime boost trial
Brice Barefoot*, Natalie J. Thornburg†, Daniel H. Barouch‡, Jae-sung Yu*, Christopher
Sample*, Robert E. Johnston†, Hua Xin Liao*, Thomas B. Kepler◊, Barton F. Haynes*, and
Elizabeth Ramsburg*,1
*Duke Human Vaccine Institute, Duke University School of Medicine, Durham NC, 27710
†Carolina Vaccine Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599
‡Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
MA, 02215
◊Department of Biostatistics and Bioinformatics, Center for Computational Immunology Duke University,
Durham NC, 27710.
Abstract
The prevention of infectious disease via prophylactic immunization is a mainstay of global public
health efforts. Vaccine design would be facilitated by a better understanding of the type and durability
of immune responses generated by different vaccine vectors. We report here the results of a
comparative immunogenicity trial of six different vaccine vectors expressing the same insert antigen,
cowpox virus B5 (CPXV-B5). Of those vectors tested, recombinant adenovirus (rAd5) was the most
immunogenic, inducing the highest titer anti-B5 antibodies and conferring protection from sublethal
vaccinia virus challenge in mice after a single immunization. We tested select heterologous prime-
boost combinations and identified recombinant vesicular stomatitis virus (rVSV) and recombinant
Venezuelan equine encephalitis virus replicons (VRP) as the most synergistic regimen. Comparative
data such as those presented here are critical to efforts to generate protective vaccines for emerging
infectious diseases as well as for biothreat agents.
1. Introduction
Immunizations against smallpox, polio, and childhood diseases such as diptheria and whooping
cough have lead to the eradication or control of these diseases [1]. The global society is now
faced with a new array of emerging or reemerging pathogens (SARS, West Nile Virus, avian
influenza) against which highly effective vaccines are urgently needed [2]. In addition, the
threat of bioterrorism, via the deliberate reintroduction of pathogens such as smallpox (variola)
is of increasing concern. It is difficult to predict when and what type of new pathogens may
emerge, thus the development of an arsenal of rapidly mobilizable vaccine platforms is highly
desirable. Ideally, the creation of a panel of vaccine vectors would allow vaccine production
utilizing a common platform technology. To date, this method of vaccine design has been
hampered by the lack of head-to-head comparison of available vaccine vectors. The goal of
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this study was to compare six different vaccine vectors in a single prime-boost immunogenicity
trial so that the relative immunogenicities of each individual vector as well as the most
synergistic prime-boost combinations could be determined.
Most human vaccines induce humoral responses to vaccine antigens in the vaccinee. The
relative importance of cellular and humoral responses to the induction and maintenance of
protection is an area of considerable controversy [3], and likely differs for each pathogen.
Despite this, passive transfer studies have shown that vaccine-induced antibody is sufficient
to confer protection against such viral infections as measles, mumps, and varicella zoster [4–
7] in humans. Similarly, induction of protective antibody has been shown to be a correlate of
protection in animal models of (re)emerging infections such as plague [8], poxviruses [9,10],
and SARS [11]. For these reasons we chose to compare vaccine vectors expressing an antigen
known to induce strong humoral responses and that was important for biodefense. The vectors
in this study expressed the 35kDa secreted form of poxvirus antigen B5. B5 is expressed on
the outer membrane of the extracellular enveloped infectious virion (EEV) and is a target of
host neutralizing antibody [12–14]. B5 is thought to be involved in long range dissemination
of poxvirus virions within the infected host [15,16], is highly conserved among mammalian
poxvirus subspecies [12,13], but does not induce measurable CD8 T cell responses in mice
[17–20]. We expressed B5 as plasmid DNA, as recombinant protein, and in non-replicating
recombinant adenovirus (rAd5), highly attenuated replication competent vesicular stomatitis
virus (rVSV), Venezuelan encephalitis virus replicon particles (VEE-VRP), and
Mycobacterium smegmatis (M. smeg) vectors. Whereas recombinant adenovirus was the most
immunogenic priming vector, recombinant VEE-VRP prime, VSV boost was the optimum
heterologous prime-boost for induction of protective anti-B5 antibodies.
2. Materials and Methods
Construction of Vaccine Vectors
Plasmid DNA—A codon-optimized encoding the 279 amino acid ectodomain of cowpox
virus (CPXV)199 (corresponding to vaccinia B5) was generated by converting the amino acid
sequence of CPXV B5 to nucleotides according to human codon usage of highly expressed
human housekeeping genes as described in [21]. The codon-optimized CPXV B5 gene was
synthesized de novo (Blue Heron Biotechnology, Bothell, WA) and subcloned into expression
plasmid pCMVR (generously provided by Dr. Gary Nabel, National Institutes of Health-
Vaccine Research Center). Plasmid DNA was purified using standard methods and was
endotoxin free and suitable for human immunization.
B5 Recombinant protein
Forward Primer 5 – TTCAGAATTCGCTAGCGTCGACGACCATGAAGACCATCTC-3
and reverse primer 5-
TTGTGGATCCGGTACCTTAGTGATGATGGTGGTGATGGTGGTAGGTGGCCT
CCAGGGACTCGATCTCCTG-3 were used to PCR amplify the ectodomain (amino acids 1
to 279) of the B5 protein of CPXV, with the addition of 5’ NheI and 3’ KpnI restriction
endonuclease sites as well as a C-terminal His6-tag. The amplified fragment was cloned into
pcDNA3.1+ (Invitrogen). Human 293T cells were transfected with the His-B5 expression
construct, and recombinant B5 protein was purified with a nickel column from culture
supernatant.
Recombinant Adenovirus—The B5 ectodomain was subcloned into the Ad5 adaptor
plasmid pAdApt. E1/E3-deleted non-replicating rAd5-B5 vectors were produced by
transfection of complementing 293 cells with pAdApt-B5 and the structural cosmid
pWE.Ad.AflIIrITR with lipofectamine (Invitrogen) in T25 flasks. Cells were passaged into
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T75 flasks after 48 hrs and maintained until virus cytopathic effect was observed. The vectors
were plaque-purified, analyzed for transgene expression, amplified in 24 triple-layer T175
flasks, purified by double CsCl gradient ultra-centrifugation, and dialyzed into PBS containing
5% sucrose. Purified rAd vectors were stored at −80°C. Virus particle (vp) titers were
determined by spectrophotometry. Specific infectivity was assessed by plaque forming unit
(PFU) assays. Dose optimization. We tested a range of doses (106 vp to 1010 vp) in order to
find the dose inducing the highest titer anti-B5 Ab. Anti-B5 Ab was not detected in mice
receiving 106vp, but increased according to dose in the 107–109 dose range (2–3 fold increase
in titer for every log difference in dose). Titers were not significantly different in mice receiving
109 vs. 1010 vp.
Venezuelan equine encephalitis replicons—VEE-VRP production has been described
previously [22]. Briefly, the coding region of the ectodomain of codon optimized CPXV199
(corresponding to vaccinia B5) was PCR amplified from plasmid DNA using primers 5-
AGTCTAGTCCGCCAAGATGAAGACCATCTCCGTGGTGACCCTGC-3 (forward) and
5-CGTTTGT ATCGAT GGATCC TTA GTGGTAGGT-3 (reverse) and inserted into VEE
replicon plasmid pVR21 [23]. Next pVR21 encoding the VEE nonstructural proteins, an
encapsidation signal, and the transgene downstream of a 26S promoter, and two helper
plasmids encoding VEE capsid and VEE E1/E2 glycoproteins were linearized and transcribed
using the mMessage in vitro transcription kit (Ambion). The attenuated V3014 glycoproteins
were used to package all VRP [24]. Transcripts were electroporated into BHK cells. VRP were
recovered from culture supernatants and were purified by ultra-centrifugation through a 20%
sucrose cushion. Concentrated VRP were resuspended in PBS and stored at −80°. Dose
optimization. We tested a range of doses (105 PFU to 107 PFU) in order to find the dose
inducing the highest titer anti-B5 Ab. Anti-B5 Ab was detected in all immunized mice and
increased according to dose (3–4 fold increase in titer for every log difference in dose).
Recombinant vesicular stomatitis virus—To obtain a plasmid that could be used to
recover an rVSV expressing CPXV199 from the first position in the VSV genome, a 840 bp
DNA fragment encoding the ectodomain of CPXV199 was amplified from pCMVR B5 using
the forward primer 5 - CCTGCAGCTCGAGACCATGAAGACCATCTCCGTGGTG -3 and
the reverse primer 5 -CTGCGACGTGCTAGCTTAGTGGTAGGTGGCCTCCAG -3 . The
forward primer introduced the underlined XhoI site upstream of the B5 coding sequence while
the reverse inserted a NheI site downstream. The PCR product was digested with XhoI and
NheI, purified, and ligated into the pVSVN4CT9 vector, which had been digested with the
same enzymes to generate pVSVN4CT9 B5. pVSV N4CT9 (generously provided by Wyeth
Pharmaceuticals) encodes a “scrambled” VSV genome and yields a highly attenuated rVSV
[25,26]. Plasmids were recovered after the transformation of Escherichia coli DH5 α
(Invitrogen) and were purified using a Plasmid Maxiprep kit (Qiagen). The insert sequence
was verified (Duke Sequencing Facility). Recombinant virus was recovered from these
plasmids as described previously. Briefly, BHK-21 cells were grown to 50% confluence and
infected at a multiplicity of infection (MOI) of 10 with vTF7-3, a vaccinia virus expressing T7
RNA polymerase (obtained from the NIH AIDS Reagent repository). One hour after infection,
cells were transfected with 10 g of pVSV1XN-GMCSF or pVSVN4CT9 B5 along with 3 µg
of pBS-N, 5 µg of pBS-P, 1 µg of pBS-L, and 4 µg of pBS-G. After 48 h, cell supernatants
were passaged onto BHK-21 cells through a 0.2-µm filter (Millipore), and medium containing
virus was collected about 24 hrs after the cytopathic effect was seen. Viruses grown from
individual plaques were used to prepare stocks that were grown on BHK-21 cells and stored
at −80°C. Dose optimization. We tested a range of doses (104 PFU to 107 PFU) in order to
find the dose inducing the highest titer anti-B5 Ab. Anti-B5 Ab was detected in all immunized
mice and increased according to dose (3–4 fold increase in titer for every log difference in
dose).
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Modified Vaccinia Ankara—MVA, originally provided at p579 by B. Moss (National
Institutes of Health), was grown on the UMNSAH/DF-1 chicken embryo fibroblast cell line
(ATCC CRL-12203). For immunization studies, MVA was purified from infected DF-1 cell
lysates by centrifugation through a 36% sucrose cushion prior to resuspension in PBS and
filtration (0.8µM). Virus infectivity was determined by plaque assay on DF-1 fibroblasts.
Mycobacterium smegmatis—M. smegmatis mc2155 was used for the generation of
recombinant M. smegmatis. All M. smegmatis cultures were grown in Middlebrook 7H9 broth
(Difco) containing 10% albumin-dextrose saline (ADS)-0.5% glycerol-0.05% Tween 80 (7).
For generation of recombinant M. smegmatis, M. smegmatis mc2155 prepared in 10% glycerol
was transformed with plasmid pJH154-B5ROct279 by electroporation with a Gene Pulsar (Bio-
Rad) set at 2.5 kV and 25 µF and with the pulse controller resistance set at 1,000. Transformed
M. smegmatis organisms were selected on Middlebrook 7H10 (Difco, Sparks, MD) agar plates
supplemented with 10% ADS containing either 30 µg/ml kanamycin. To monitor the
expression of B5, individual colonies of recombinant M. smegmatis grown in Middlebrook
7H9-ADS-Tween broth in the presence of 30 µg/ml of kanamycin were harvested by
centrifugation. After a rinse with sterile phosphate-buffered saline, mycobacterial cells were
lysed by using the modified extraction buffer with 106-µm glass beads (Sigma) and cell lysates
were cleared by centrifugation. The lysate of recombinant M. smegmatis was fractionated by
4 to 20% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and blotted onto
nitrocellulose filters (Schleicher & Schuell, Germany). Dose optimization. We tested a range
of doses (106 PFU to 108 CFU) in order to find the dose inducing the highest titer anti-B5 Ab.
Anti-B5 Ab was detected in mice immunized with 107 and 108 but not 106 CFU. Titers
increased according to dose (~2 fold increase in titer for every log difference in dose).
Mice and Immunizations—Ten-week-old female C57BL/6 mice were purchased from
Jackson Laboratories and housed for at least 1 week before experiments were initiated. Mice
were housed in micro-isolator cages in a biosafety level 2-equipped animal facility. Vaccine
stocks were diluted to appropriate titers in sterile 1xPBS immediately prior to immunization.
For intramuscular vaccination, mice received a single 50µl injection in the right quadriceps.
For intranasal immunization mice were anesthetized using an isofluorane vaporiser, and
inoculated with 30µl of the appropriate vaccine (15µl per nostril). The Institutional Animal
Care and Use Committee of Duke University approved all animal experiments. Vaccine dose
amounts for the intramuscular and intranasal immunizations were the same. Doses for each
vaccine vector were: 50µg B5 plasmid DNA, 50µg B5 protein administered with oligo CpG
adjuvant, 2.5×106 IU VRP-B5, 1.0×108 CFU M. smegmatis B5, 1.0×109 VP rAd5-B5,
5.0×106 PFU rVSV N4CT9 B5, 1.0×107 PFU MVA. Mock immunized mice received 50µl
sterile diluent.
Verification of B5 Expression—B5 expression was verified in each vaccine vector via
western blotting for B5. Briefly, samples were prepared as appropriate for each vector and
resolved by SDS-PAGE. No attempt was made to equalize protein loading between disparate
samples (i.e. DNA and VRPs). Gel was transferred to nitrocellulose and blotted with polyclonal
rabbit serum from rabbits immunized with CPXV-B5 protein. Bands were visualized using
Western Blue stain (Promega).
ELISA for binding Antibody—Immulon II ELISA plates (96 well, polystyrene) (Fisher)
were coated with purified B5 (200 ng per well) in bicarbonate buffer (0.1M NaHCO3)
overnight at 4 °C. Wells were washed, blocked with Superblock (15% Normal Goat Serum,
0.04% Whey in PBS-Tween) and incubated with diluted sera. Antibody was detected with
alkaline-phosphatase conjugated goat anti-mouse Ig and antibody reactivity was detected by
adding pNPP substrate (4-nitrophenyl phosphate Sigma N2640) at 1mg/ml as directed by the
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manufacturer incubating for 45 minutes and reading Abs at 405nm. Serum Ig endpoint titers
are reported as the reciprocal of the highest dilution that gave absorbance greater than 2x over
background, where background is the absorbance for pre-immune serum at the same dilution.
All animals were assayed individually, and compared to individual pre-immune titers.
Ammonium Thiocyanate Competitive Binding ELISA—Corning 3700 384 well micro
titer plates were coated with purified B5 (60ng per well) in bicarbonate buffer (0.1M
NaHCO3) overnight at 4°C. Wells were washed, blocked with Superblock (15% Normal Goat
Serum, 0.04% Whey in PBS-Tween20) and incubated with sera in the appropriate dilutions,
as determined earlier in the IgG binding ELISA, to give an Optical Density (OD) between 1.5
and 2 when read at 405nm. The optimal dilutions were then replicated down the columns of
the plate and incubated for 2hrs at room temperature. The plates were washed and 30ul of
various concentrations of Ammonium Thiocyanate (NH4SCN) ranging from 4M to 0M diluted
in sodium phosphate buffer (20mM NaH2PO4) were added to each column in decreasing
molarity and incubated for 15 minutes. The plates were washed and incubated with AP-
conjugated goat anti-mouse Ig (Sigma A3562) for 1hr and then washed. Bound serum IgG was
detected by adding pNPP substrate (4-nitropenyl phosphate Sigma N2640) at 1mg/ml as
directed by the manufacturer and incubated for 45 minutes and then read at 405nm. All samples
were run in duplicate and compared to the initial absorbance (OD0 = 0M) in absence of
NH4SCN for each sample by using a simple regression line. Absorbance readings in the
presence of increasing concentrations of NH4SCN were converted to a percentage of the initial
absorbance in the absence of NH4SCN. The data were graphed with the x-axis representing
the molar concentrations of NH4SCN and the y-axis representing the percent initial absorbance.
The binding index was estimated as the molar concentration of NH4SCN required to reduce
the initial absorbance by 50%.
Comet Reduction Assay—Corning 3506 6 well tissue culture plates were seeded with
3×106 African green monkey (BSC-1) cells using 2mls/well of Dulbecco’s modified Eagle
Medium (DMEM) containing 10% heat-inactivated fetal bovine serum (FBS) and 100units/ml
of penicillin and 100ug/ml of streptomycin. Plates were incubated overnight at 37°C and 5%
CO2. Vaccinia virus strain International Health Department – J (IHD-J) (provided by Dr.
Richard Moyer, University of Florida) was sonicated for 10 minutes in a water bath and then
diluted in sera and antibiotic free DMEM to yield 15 to 30 plaques per ml. The cell monolayers
were washed once using DMEM 2% FBS with pen/strep and 1ml of the diluted IHD-J was
added to each well and incubated for 1hr at 37°C. After the 1hr absorption the virus inoculum
was removed and each sample of mouse sera containing the neutralizing antibodies was added
in the amounts of 50ul in well 1, 100ul in well 2, and 200ul in well 3 giving a total of 2 samples
across each plate with 3 separate dilutions of antibody for each sample. 2mls per well of DMEM
2% FBS containing pen/step was added and plates were incubated at 37°C for 72hrs. Media
was removed and monolayers were stained with crystal violet to visualize comet formation/
reduction.
3. Results
3.1 Construction and recovery of vaccine vectors expressing CPXV B5
B5is a 42kDa glycosylated type I membrane protein located in the outer membrane of the
extracellular enveloped virion (EEV)[27]. B5 is conserved among poxviruses and has
homologues among many mammalian orthopoxviruses including variola and vaccinia [12,
13]. The B5 ectodomain (B5t) encompasses four domains with resemblance to short consensus
repeats (SCRs) present in complement regulatory proteins, plus a 51 amino acid stalk next to
the transmembrane region [12,28]. Epitope mapping studies have suggested that the stalk
interacts with the first two SCR domains and that these regions are important neutralizing sites
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[14]. Vectors in this study expressed a codon-optimized truncated B5 (35kDa) from which the
transmembrane and cytoplasmic domains have been removed (Figure 1A). Detailed description
of vaccine vector construction is provided in the Methods section. Figure 1B shows a western
blot of all B5 expressing vaccine vectors except for M.smegmatis. M.smegmatis expressed very
low levels of the B5 protein which could not be readily detected by western blotting. All other
vectors expressed robust levels of B5 protein. While the expression of B5 by M. smegmatis
was barely detectable by western blot the presence of the gene was confirmed by sequencing.
3.2 Primary immunization with vaccine vectors expressing CPXV B5 induced high titer anti-
B5 serum antibody
To determine whether vaccination with B5 expressing vaccine vectors could induce primary
immune responses in mice we immunized adult C57BL/6 mice with each vector and measured
serum antibody titers to B5 via binding ELISA. Doses for each vector are listed in the Methods
section and the immunization schedule is shown in Figure 1C. In order to standardize the
immunization protocol as much as possible we elected to give all immunizations
intramuscularly in a single 50µl injection for which the diluent was sterile saline. Thus for all
priming vector studies, the only variable was dose and vaccine vector. Dosing for each vector
was based on individual preliminary experiments in which the dose giving optimal immune
responses was determined (dose range tested is provided in Methods). For rVSV and the VRP
the dose was limited by the amount of virus that could be delivered in the 50µl inoculation
volume. Primary humoral responses to B5 were assayed at four (data not shown) and six weeks
(Figure 2) post immunization by binding ELISA. Titers did not change significantly for any
group between four and six weeks post immunization. All vectors induced detectable serum
antibody titers except for M. smegmatis. Anti-B5 antibodies were not detected in any of the 48
animals immunized with M. smegmatis B5. This was potentially because the M. smegmatis
vector expressed inadequate levels of B5 protein to induce a detectable immune response. All
six immunization groups were compared statistically in a single ANOVA with multiple
comparison analysis (Tukey). rAd5 induced significantly higher primary anti-B5 antibody
titers than any other vector tested (P<10−6, ANOVA with Tukey multiple comparison test).
Recombinant protein with oligoCpG induced significantly higher titers than all other vectors
except rAd5 at the 0.05 significance level. There were no significant differences in the anti-
B5 titers induced by rVSV and VRP vectors. Titers induced by DNA were significantly lower
than all other groups tested at the 0.05 significance level.
3.3 Heterologous boosting with vectors expressing CPXV B5 increased anti-B5 serum
antibody
Six weeks after the single primary immunization all animals were boosted with a single dose
of either rAd5-B5 or rVSV N4CT9 B5. These boosting vectors were chosen because both have
been shown, in numerous studies, to induce synergistic responses when incorporated into
heterologous prime-boosting regimens [29–33]. Additional cohorts of animals were
immunized with the boosting vector alone, as a control. Serum was collected at two weeks
after the boost, then at one, two, and three months post boosting and assayed individually for
anti-B5 titers via binding ELISA. Anti-B5 serum Ab titers increased for all groups after
boosting. Data from all groups and all time points is shown in Table 1, with the peak titer for
each group indicated by shading. Figure 3 shows the average peak titer for each prime-boost
group, where each individual animal’s peak titer was determined independent of the time at
which that titer was reached. Average peak titers were then calculated for each group.
Immunization groups fell into three “tiers” based on peak titer, as indicated in Table 1. For
simplicity, we discuss the statistical analyses performed using the average peak titers for each
group. The overall ranking of prime-boost effectiveness was the same when we used titers at
the latest timepoint (3 months post boost) versus the average peak titers calculated independent
of time. In the top group, inducing the highest overall titers, were protein prime-Ad5 boost,
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protein prime-VSV boost, and rAd5 prime-VSV boost. An optimal prime boost regimen
induces post-boost antibody titers that are a) higher than the titers achieved by primary
immunization and b) higher than titers achieved by the boosting vector alone. In these
experiments, all prime boost regimens (except for Ad5 prime VSV boost, P=0.0651, ANOVA)
satisfied the first criteria, i.e. for all groups peak post boost titers were significantly higher than
those induced by the primary immunization alone (P<10−6, ANOVA with Tukey multiple
comparison test) for all groups where primary titers were compared to post boost titers. A single
primary immunization with rAd5-B5 induced average peak titers of 39,307. We compared the
titers resulting from heterologous prime-boost regimens in which rAd5 was the boosting vector
versus those induced by immunization rAd5 alone we found that the only rAd5 boosted regimen
that induced significantly higher post-boost titers was protein prime-rAd5 boost (Student T
test, P<10−6). This indicates that priming with B5 protein significantly augmented the titers
that could have been achieved by immunizing with rAd5 alone. For all other Ad5 boosted
groups tested, the P value was greater than 0.05, indicating that there was no effect of priming.
In contrast, all regimens in which rVSV was the boosting vector induced titers significantly
above the primary response to rVSV, which was a GMT of 300 (for all groups P<10−6, except
for M.smeg/VSV for which P=0.00376, Student T test). This indicates that priming with a
heterologous vector added significantly to the titers that could have been achieved by
immunizing with rVSV alone (unless the priming vector was rAd5), and suggests that rVSV
was a synergistic boosting vector, while rAd5 generally was not. In order to determine
quantitatively which prime boost combinations were the most synergistic we defined synergy
mathematically as : synergy=log10 (TPB/TP+TB) where TPB is the post boost titer, and TP and
TB are the titers induced by the priming and boosting vectors alone. If the post boost titer were
the sum of the titers induced by the priming and boosting vectors when delivered singly, then
by definition there would be no synergy and the estimated value for the synergy would be zero.
The most synergistic prime boost combinations were those for which the post boost titers were
the most increased relative the primary responses to both the priming and boosting vectors
considered separately. By this calculation all prime-boost groups tested had positive synergy.
Of these, VRP-VSV, DNA-VSV, and protein-VSV were the most synergistic prime boost
combinations, and were significantly (at the 0.05 level) more synergistic than other prime-
boost combinations tested; the synergies within this group did not differ among themselves at
the 0.05 significance level.
3.4 Boosting with rAd5 induced anti-B5 antibody of higher avidity than does rVSV boosting
The results presented above demonstrate that most of the prime-boost regimens tested
generated high titer anti-B5 antibodies. In many cases, vaccine efficacy depends not only upon
the amount of antibody generated but upon the strength of binding of the immunoglobulin to
the antigen. To determine whether the avidity of the anti-B5 antibodies generated differed with
vaccine regimen we performed competitive binding ELISAs. The absolute amount of anti-B5
Ab between samples was equalized, and binding titers were determined in the presence of
increasing molar quantities of ammonium thiocyanate (NH4SCN). The “avidity index” was
defined as the amount of NH4SCN necessary to reduce binding by 50%. Higher avidity Ab-
Ag interactions require higher concentrations of NH4SCN to disrupt. After the single primary
immunization, animals immunized with rAd5 had the highest avidity Ab (Figure 4A).
Antibodies from animals immunized with protein, VRP, and DNA had approximately equal
avidities, which were much lower than those generated by rAd5. Antibody titers in M.
smegmatis immunized animals were too low to be measured, therefore sera from those animals
were not included in this analysis. An ideal vaccine regimen would induce immune response
which mature (i.e. increase in avidity) over time. To determine which of our vaccine regimens
fulfilled this requirement we assayed avidity at two weeks (Figure 4B and C) and at two months
(Figure 4D and E) after the single booster immunization. Boosting with rAd5 raised and
equalized avidity of Ab in all groups by two weeks post boost (Figure 4B) and the higher avidity
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Ab were maintained at the two month timepoint (Figure 4D). In contrast, VSV boosting did
not raise avidity of the Ab in VRP or DNA primed animals by two weeks after the boost. By
two months post-boost DNA-VSV animals had Ab of increased avidity, but VRP-VSV
immunized animals never reached a higher avidity than those induced by VRP priming alone.
3.5 Antibody induced by rAd5 immunization restricts viral dissemination
One important mechanism of action for antibody is the ability to neutralize whole virus and/
or to restrict dissemination of progeny virions. The ability of anti-poxvirus antibodies to restrict
viral spread can be assessed via “comet assay”. Vaccinia strain IHDJ (vIHDJ) is a mutant strain
producing a large number of EEV particles, which mediate long range dissemination in the
infected host. In vitro, vIHDJ forms characteristic “comets” as EEV are released into the culture
medium. When vIHDJ plaque assays are performed in the presence of antibody capable of
binding and neutralizing EEV, comet tails are reduced or eliminated. Figure 5 shows results
of comet assays performed using pooled post-immune sera from mice vaccinated with the B5-
expressing vectors. After the primary immunization, sera collected from rAd5 immunized mice
was the only sample that neutralized comet formation (Figure 5, left panel, row 6). After
boosting with rAd5 (Figure 5, middle panel), or VSV (Figure 5, right panel), all sera tested
neutralized comet formation when used at the highest amount. After boosting, comet
neutralizing activity was present in all samples, even in those at which the B5 Ab was present
in significantly lower quantity than in samples which failed to neutralize after the primary
immunization. This shows that the ability to restrict viral dissemination in this assay is not
solely a function of the amount of Ab in the serum, but reflects functional differences in the
Ab itself.
3.6 Intramuscular immunization with B5-expressing vectors protects mice from sublethal
challenge with vvWR
The data presented so far demonstrate that immunization with B5-expressing vaccine vectors
induced high titer serum Ab against B5 that was able to restrict viral spread in an in vitro assay.
To determine whether our results in vitro correlated with function in vivo we challenged
immunized mice with vaccinia WR (vvWR). Since an immune response directed at a single
poxvirus antigen rarely confers full protection from lethal challenge we decided to challenge
our animals with a sublethal dose of vvWR. The sublethal dose caused significant weight loss
(of up to 30% pre-challenge body weight) in naive control animals and a mortality of 50–80%.
Mice were immunized intramuscularly with B5-expressing primary and boosting vectors, and
three months after the boost were challenged intranasally with 1×105 PFU vvWR. Figure 6
shows average pre-infection body weight for rAd5 (Figure 6A) and VSV (Figure 6B) boosted
animals (n=12–24 mice per group). Animals primed and boosted with MVA were included as
a positive control for protection (n=12). By four days post challenge mock immunized control
animals began to lose weight and show signs of illness. By ten days post challenge eight out
of the twelve mock immunized control animals died or had been sacrificed in accordance with
our animal protocol (66% mortality). All animals boosted with rAd5 survived, regardless of
primary immunization. Among VSV boosted animals only three animals died, one in the DNA
primed group and two in the M. smegmatis primed group. VSV boosted groups showed overall
greater pathology after challenge, with more severe and prolonged weight loss. Pathology
correlated on a group and an individual animal level with serum Ab titers pre-challenge, with
animals having higher titers showing less pathology after challenge.
3.7 Single dose immunization with rAd5 but not rVSV was sufficient to prevent pathology
after intranasal challenge with vvWR
To determine whether intramuscular immunization with a single dose of either of the boosting
vectors was enough to confer protection from challenge we immunized separate cohorts of
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animals with either rAd5-B5 or rVSV-B5 (n=15 mice per group) as described in Figure 2.
Three months after the single immunization all animals were challenged with a sublethal dose
of vvWR as in Figure 6A–B. Figure 6C shows average pre-infection body weight for all groups
after challenge. Animals immunized with a single dose of rAd5-B5 lost very little weight and
showed only minimal signs of illness. In contrast, mock immunized and rVSV-B5 immunized
animals lost weight rapidly from day 4 on and showed signs of clinical illness and respiratory
distress. All rAd5 immunized animals survived, eight out of fifteen rVSV immunized animals
(53% survival), and four out of ten (40% survival) mock immunized animals survived. The
difference between the survival rate of rVSV and mock immunized animals was not statistically
significant (P=0.398, Mantel-Cox Log-rank test). These data demonstrated that a single
immunization with rAd5 but not rVSV was sufficient to confer protection against pathology
caused by sublethal challenge with vvWR.
3.8 Intranasal immunization generated higher titer antibody than intramuscular
immunization
One challenge to vaccination is the use of needles for vaccine delivery. To determine whether
our vaccines were immunogenic when delivered by a needle-free route, we tested
immunogenicity of three vectors given intranasally. Since there is a large body of pre-existing
literature describing the delivery of protein vaccines via the intranasal route we chose to
investigate prime boost combinations of our other three most immunogenic vectors: rAd5,
VSV, and VRP. To determine whether intranasal vaccination with B5 expressing vaccine
vectors could induce primary immune responses comparable to those induced by intramuscular
immunization in mice we immunized adult C57BL/6 mice with each vector and measured
serum antibody titers to B5 via binding ELISA. Doses for each vector were the same as those
in the intramuscular experiment and volume for all intranasal inocula was 30µl per mouse. At
six weeks after the primary immunization, all three vaccine groups had significantly higher
titers (P<10−6 for VRP and VSV, and P=0.000158 for rAd5, ANOVA) than were generated
by intramuscular immunization (Figure 7A). Intranasal delivery of VSV and VRP increases
titers more than 10x over those generated by intramuscular delivery, while rAd5 generated
titers increased 2.5x. After heterologous boosting, all animals showed greatly increased serum
Ab titers, with rAd5 primed-VRP boosted animals having the highest overall titers (Figure 7B).
In general, titers generated by intranasal prime-boosting were much higher than those generated
by intramuscular immunization, with all groups having an average peak endpoint titer of at
least 1:100,000. These data demonstrated that rAd5, VSV, and VRP vectors were more
immunogenic when delivered intranasally, and suggests that delivering vaccines intranasally
may lead to the induction of better immune responses with the same amount of antigen (dose
sparing) relative the intramuscular route.
3.9 Intranasal immunization with B5-expressing vectors protects mice from sublethal
challenge with vvWR
To determine whether the anti-B5 antibody generated by intranasal immunization was
protective in vivo we challenged immunized mice with vaccinia WR (vvWR) as in Figure 6.
As in the intramuscular immunization experiment, mice were challenged three months after
the single booster immunization. Figure 7C–E shows average pre-infection body weight for
intranasally vaccinated animals. By four days post challenge mock immunized control animals
began to lose weight and show signs of illness. By ten days post challenge eight out of the ten
mock immunized control animals had died (80% mortality). None of the vaccinated (n=20 per
group) mice died. There were no statistically significant differences in the amount of weight
lost between the different B5-immunized groups (ANOVA, P=0.0526), although three of the
six prime groups tested showed essentially no pathology after challenge (VRP-VSV, VSV-
VRP, and rAd5-VSV). For these three groups, the average percent initial body weight never
fell below 95% (Figure 7F). This was in contrast to intramuscularly immunized animals, in
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which the best protected groups still declined to below 90%. This suggested that intranasal
immunization was a better route for some vaccine regimens.
4. Discussion
In this study we tested six vaccine vectors to determine which were a) the most immunogenic
and protective at the tested doses and b) most appropriate for developing vaccines against
emerging biothreats. The vaccine antigen (CPXV B5) was the same for all vectors, as was the
route of immunization and volume of inoculum. Because the vaccine vectors were intrinsically
different, dose could not be measured in the same units for all vectors, but was chosen in order
to maximize immunogenicity of each. We also elected to use doses that could feasibly be
produced using current vaccine manufacturing techniques. Recombinant adenovirus was the
most immunogenic of the six priming vectors tested, inducing significantly higher serum
antibody titers than the other immunizations. rAd5-induced antibodies induced were of higher
avidity than those induced by the other vectors, and were the only antibodies able to reduce
the spread of vaccinia EEV in vitro. In addition, a single dose of rAd5-B5 protected animals
from intranasal challenge with vaccinia virus. This finding is consistent with a recent report
by Kaufman et al [34] in which the authors reported that animals immunized with rAd35-based
vectors expressing different poxvirus IMV and EEV Ag protected mice from lethal poxvirus
challenge.
Our data show that rAd5 is a good “stand-alone” vector that could be used in situations in
which development of humoral responses in a short period of time is necessary for protection
and in which traditional vaccines have induced suboptimal responses. For example, if a highly
pathogenic H5N1 human-transmissible influenza strain emerges, single dose immunization
with a rAd5 vector expressing the relevant H5 HA might protect vaccinated individuals.
Despite the fact that rAd5 vectors are highly immunogenic, any future use of rAd vaccine
vectors in humans will have to take into consideration the results of the recent Merck HIV
vaccine trial [35]. In that trial human volunteers with preexisting antibodies to rAd5 and
vaccinated with a rAd5 similar to the vector in this study were more vulnerable to HIV infection
than individuals receiving saline [36,37]. The mechanism by which infection was enhanced
has not been determined, but one possible explanation is that rAd5 immunization of rAd5-
exposed individuals activated rAd-specific memory T cells. HIV preferentially infects
activated memory T cells, and thus infection may have been potentiated in individuals
encountering HIV during the time that rAd5-specific T cells were activated. If that is true, then
rAd5-based vaccines can probably safely be used to vaccinate against pathogens that do not
preferentially infect activated lymphocytes. Nonetheless, in light of the Merck trial, defining
good alternatives to rAd vectors is imperative.
In this study the prime-boost combination of rVSV and VEE-VRP was highly synergistic for
antibody induction and protected mice from challenge with vaccinia. The synergy of rVSV
and the VEE-VRP may be due to the fact that these vectors trigger multiple and complementary
pathogen recognition receptors, and that these vectors efficiently infect dendritic cells [38,
39]. All three vectors tested (rAd5, rVSV, VEE-VRP) induced significantly higher titer
antibodies and better protection when delivered intranasally than when delivered
intramuscularly. Intranasal delivery of these viral vectors may result in activation of a different
population of antigen presenting cells, an enhanced cytokine response, or a different amount
of antigen production relative intramuscular immunization. Future experiments will focus on
determining the precise mechanism of enhanced protection after intranasal vaccination and
whether intranasal vaccination enhances responses to all, or to a subset, of vaccine antigens.
The most important goal for follow-on studies arising from this work will be to identify the
mechanisms responsible for the observed differences in immunogenicity between the different
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vectors. Factors potentially affecting relative immunogenicity of the vaccine vectors include:
1) the number and type of host cells targeted by each vector, 2) the “adjuvanting” effect of the
vector itself due to the capacity of the vector to activate TLR or other innate pathways, 3) the
amount of antigen produced by the vector and the amount of replication (if any) of the vector
in vivo, 4) the duration of vector/ antigen expression, and 5) the quality of the helper T cell
response induced by each vector. It is very likely that the response to the vectors could be
altered by a variety of means including increasing vaccine dose (thereby increasing the amount
of Ag produced), changing the route of delivery (and the number and type of target cells
affected), or by adding additional adjuvants (such as those known to bind TLR). The viral
vectors (rAd5, VSV, VRP) are expected to stimulate similar innate pathways, target similar
numbers of host cells, and to persist for similar lengths of time. In view of this, one important
question raised by these studies is why the rAd5-B5 vector was so much more immunogenic
(when delivered intramuscularly) than the other viral vectors (VSV and VRP). One possibility
is that differences in replication competence influenced immunogenicity. The rVSV used in
these experiments is highly attenuated but can replicate in vivo [25,26], while the rAd5 and
VRP constructs are fully replication deficient. The ability to replicate usually increases rather
than decreases immunogenicity. Since the VRP and rVSV vectors were administered at similar
doses (2.5×106 PFU and 5×106 PFU respectively) we would expect the rVSV vector to induce
higher titers than the VRP vector if replication competence positively influenced the induction
of humoral responses. Instead, titers generated by rVSV were not significantly different (and
in fact were somewhat lower) than those generated by the VRPs. So, while we cannot conclude
absolutely that replication competence did not affect the outcome of our study, it seems that
other factors balanced the contribution of replication competence to immunogenicity.
Interestingly, fully VSV-G deleted vectors (which do not replicate) have been shown to be of
equal or greater immunogenicity to replication competent rVSV expressing the same antigen
[40]. Thus it is unlikely that the immunogenicity of the VSV could have been enhanced by
using a less attenuated construct. Another reason why rAd5 induced better immune responses
than the VRP and rVSV vectors may have been that it was administered at a higher dose
(1×109 VP vs. 2.5–5×106 PFU). In preliminary dose-optimization studies, higher doses
uniformly induced higher Ab titers, although the fold-increase was not the same for all. This
suggests that if we had been able to administer equal doses of rVSV, VRPs, and rAd5, we
might have obtained immune responses of equal magnitude with all viral vectors, although
qualitative differences (i.e. in affinity) may have remained. Consistent with this, delivering the
three viral vectors by the intranasal rather than intramuscular route greatly decreased the
disparity in response between rAd5, rVSV, and the VRPs, even though the doses of all three
vectors in that experiment were the same as those used in the intramuscular trial. This
demonstrates that factors other than dose (route of delivery, target organ) can profoundly
influence the immune responses generated by vaccination.
The goal of this study was to test vaccine vectors as they might be used in real vaccines for
human patients. rAd5 vectors have been injected into humans at doses of up to 1012 PFU for
gene therapy applications. If equivalent doses of VRP or highly attenuated rVSV vectors can
be formulated and administered safely, it is likely that all three vectors could be used in
heterologous prime-boost combinations to induce robust humoral responses to a variety of
agents.
The strength of this study is that as many variables as possible were held constant, allowing a
head-to-head comparison of immunogenicity. This study provides a starting point for further
mechanistic studies, which can elucidate the molecular interactions which give rise to the
differences in immunogenicity between these vaccine vectors.
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Figure 1. Vaccine vectors express CPXV-B5
Vaccine vectors in this experiment were constructed to express a truncated CPXV-B5 (35kD)
from which the transmembrane and cytoplasmic domains have been deleted. A schematic
drawing of the CPXV gene insert is shown in Panel A. CPXV-B5 expression was verified in
each vaccine vector via Western blotting for B5 (Panel B). Samples were prepared as
appropriate for each vector (lysates of infected or transfected cells) and resolved by SDS-
PAGE. No attempt was made to equalize protein loading between different samples (i.e. DNA
and VRPs). A lysate of cells infected with modified vaccinia Ankara (MVA, lane 5) was
included as a positive control for B5 expression. The B5 expressed by MVA is the native non-
truncated (42kD) form while the other vectors express the truncated 35kD form.
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Figure 2. Primary responses to immunization with B5-expressing vaccine vectors
Adult female C57BL/6 mice were immunized with a single intramuscular injection of B5
expressing vaccine vectors. Six weeks after immunization all mice were bled and anti-B5 titers
determined by binding ELISA (n= 48 mice per group for DNA, protein, VRP, and M.
smegmatis, n=24 mice per group for rAd5, rVSV, and mock immunized). All sera were assayed
individually. Endpoint titers were defined as the dilution reading 2x over background where
background was the reading for pre-immune sera for each individual animal. Bars on graph
are the geometric mean titer for each immunization group and error bars represent the upper
and lower limits of the 95% confidence interval. Data shown is compiled from two duplicate
experiments.
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Figure 3. Boosting with heterologous vectors increases serum antibody titers to B5
Adult female C57BL/6 mice were immunized with a single intramuscular injection of B5
expressing vaccine vectors as indicated in Table 1. Six weeks after primary immunization all
mice were boosted with a single booster immunization of either rAd5-B5 (open bars), or rVSV-
B5 (shaded bars). Animals were bled at multiple timepoints after boosting (from two weeks to
three months post boost) and sera were assayed individually for anti-B5 binding activity.
Endpoint titers were defined as the dilution reading 2x over background where background
was the reading for pre-immune sera for each individual animal. Bars on graph are the peak
geometric mean titer for each immunization group and error bars represent the upper and lower
limits of the 95% confidence interval. The peak titer was the highest anti-B5 titer reached by
an individual animal regardless of the time at which that titer was reached. All groups contained
12 animals.
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Figure 4. rAd5 immunization induces higher avidity antibody than do other vaccine regimens
Individual sera from mice immunized intramuscularly with B5-expressing vectors were
assayed for avidity via competitive binding ELISA. Graphs show binding curves for sera
collected six weeks after the primary immunization (Panel A), two weeks after the single
booster immunization (Panels B and C), and two months after the boost (Panels D and E). The
calculated average avidity index for each group is indicated in the graph legend. Avidity index
was defined as the concentration of NH4SCN required to reduce binding of an individual
sample by 50%. Each sample was assayed in quadruplicate. Data shown is from the first large-
scale immunization experiment, in which there were at least 24 mice per group prior to the
boost, and 12 mice per group after the boost. Avidity indices were also calculated from samples
collected in the second experiment, and were identical to those shown here.
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Figure 5. Antibody induced by rAd5 immunization restricts viral dissemination
Pooled sera from mice immunized intramuscularly with B5-expressing vectors were assayed
for the ability to inhibit comet formation by vaccinia IHDJ. Figure shows representative plaque
assays for each group of pooled sera. BSC-1 cells were infected with approximately 50 PFU
of vIHDJ in the presence of 50, 100, or 200µl of the indicated post-immune sera. Sera tested
in this assay were collected at three months after the boost. A reduction in the formation of
comet “tails” indicates the presence of neutralizing Ab.
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Figure 6. Heterologous prime-boosting confers protection from weight loss after intranasal
challenge with vaccinia WR
Mice were primed and boosted intramuscularly with B5-expressing vectors as described in
Figure 3. Three months after the single booster immunization all animals were challenged
intranasally with 1×105PFU vvWR. Graphs (Panel A and B) show average percent initial
weight±SEM for immunized and control animals by group (n=12 per group). Animals losing
20% or more of their pre-infection body weight were euthanized in accordance with our animal
protocol. By day 10 after challenge 8 out of the 12 mock immunized control animals were
dead. To determine whether immunization with the boosting vector alone could protect animals
from challenge we immunized separate cohorts of mice intramuscularly with 1×109 VP rAd5-
B5 or 5×106 PFU rVSV-B5. Three months after immunization mice were challenged
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intranasally with 1×105PFU vvWR. Graph (Panel C) shows average percent initial weight
±SEM for immunized (n=15 per group), mock immunized control (n=10), and mock challenged
(n=5) animals by group. All rAd5 immunized mice survived. rVSV and mock immunized mice
had survival rates of 53% and 40% respectively.
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Figure 7. Intranasal immunization generates high titer anti-B5 antibody and protects animals from
sublethal challenge
Adult female C57BL/6 mice were immunized with a single intranasal inoculation of B5
expressing vaccine vectors as indicated in Table 1. Six weeks after primary immunization all
mice were boosted with a single booster immunization of either rAd5-B5, VRP-B5, or rVSV-
B5. Doses for the boost were the same as for the prime. Animals were bled after primary (Panel
A) and booster (Panel B) immunization and sera were assayed individually for anti-B5 binding
activity. Endpoint titers were defined as the dilution reading 2x over background where
background was the reading for pre-immune sera for each individual animal. Bars on graph
are the peak geometric mean titer for each immunization group (n=20 per group) and error bars
represent the upper and lower limits of the 95% confidence interval. Three months after the
boost all animals all animals were challenged intranasally with 1×105PFU vvWR. Graphs
(Panel C–E) shows average percent initial weight±SEM for immunized and control animals
by group (n=20 per vaccine group). All plots shown are from the same experiment, but have
been shown as three separate graphs for clarity. By day 10 after challenge 5 out of the 10 mock
immunized control animals were dead. Panel F shows the maximum percent weight loss by
group after challenge. Bars represent average ±SEM for each group. The difference in
maximum weight loss was not statistically significant among the immunization groups
(ANOVA, P=0.0526).
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